Pharmaceutical

BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer

The Opdivo/Yervoy combination demonstrated statistically and clinically significant improvements in the Phase III CheckMate-9DW study.

Jul 20, 2024 - 04:00
BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer
The Opdivo/Yervoy combination demonstrated statistically and clinically significant improvements in the Phase III CheckMate-9DW study.
Read the original article

Tags:

Previous Article

Global study by Hawaiʻi Institute of Marine Biology demonstrates benefit of mari...

Next Article

Tech leader’s $125m boosts Parker Institutes immunotherapy research

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: J&J cuts the price of its lifesaving TB pill by more than half for many low- and middle-income countries

STAT+: J&J cuts the price of its lifesaving TB pill by ...

Aug 31, 2023

Century secures $60m in stock sale and buys preclinical cell therapy biotech

Century secures $60m in stock sale and buys preclinical...

Apr 13, 2024

Sun Pharma and Philogen sign licence agreement for anti-cancer therapy

Sun Pharma and Philogen sign licence agreement for anti...

May 30, 2023